Lung cancer patients with positive programmed death‐ligand 1 expression endure graver postoperative pain

Lu Wang,Jian Zhou,Huixin Liu,Hao Xu,Huifang Li,Yi Feng,Xue Tian
DOI: https://doi.org/10.1002/ejp.2056
2022-11-14
European Journal of Pain
Abstract:Background Postoperative pain after video‐assisted thoracoscopic surgery (VATS) is common in lung cancer patients, and it is unclear whether cancer itself participates in pain regulation. Programmed cell death ligand‐1 (PD‐L1) expressed by tumors may be analgesic. Our study aimed to detect the association between PD‐L1 and acute postoperative pain. Methods We reviewed patients who underwent VATS for lung cancer with tumor PD‐L1 expression analyzed in our center from Jan 2017 to Jul 2020. They were divided into PD‐L1 (‐) group and PD‐L1 (+) group and were further divided into four subgroups according to opioids for postoperative analgesia: sufentanil PD‐L1 (‐), sufentanil PD‐L1 (+), oxycodone PD‐L1 (‐), and oxycodone PD‐L1 (+). We compared the numeric rating scale (NRS) for the first three postoperative days at rest or cough between groups. Results A total of 369 patients (167 in PD‐L1 (‐) vs. 202 in PD‐L1 (+)) were included. On the first postoperative day, NRS at cough in the PD‐L1 (+) patients were higher than those in the PD‐L1 (‐) patients (2.91 ±1.07 vs. 2.66 ±1.01, p=0.018). On the third day, NRS at cough in PD‐L1 (+) patients was higher (2.50 ±1.02 vs. 2.26 ±1.09, p=0.043). For patients with oxycodone, NRS was higher in PD‐L1 (+) than in PD‐L1 (‐) (p=0.041) at cough after surgery. In contrast, those with sufentanil did not significantly differ in NRS between groups. Conclusions Patients with PD‐L1 (+) suffered graver pain in the early postoperative period after VATS for lung cancer compared with PD‐L1 (‐) on tumors. Analgesia with sufentanil seemed to overcome this effect better than oxycodone.
neurosciences,clinical neurology,anesthesiology
What problem does this paper attempt to address?